[go: up one dir, main page]

ATE397676T1 - Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen - Google Patents

Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen

Info

Publication number
ATE397676T1
ATE397676T1 AT05815224T AT05815224T ATE397676T1 AT E397676 T1 ATE397676 T1 AT E397676T1 AT 05815224 T AT05815224 T AT 05815224T AT 05815224 T AT05815224 T AT 05815224T AT E397676 T1 ATE397676 T1 AT E397676T1
Authority
AT
Austria
Prior art keywords
differentiation
leukemia cells
mirnas
identification
myelogene
Prior art date
Application number
AT05815224T
Other languages
English (en)
Inventor
Olivier Voinnet
Charles-Henri Lecellier
Anne Saumet
Michel Lanotte
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE397676T1 publication Critical patent/ATE397676T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05815224T 2004-11-03 2005-11-03 Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen ATE397676T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0411725A FR2877350B1 (fr) 2004-11-03 2004-11-03 IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE

Publications (1)

Publication Number Publication Date
ATE397676T1 true ATE397676T1 (de) 2008-06-15

Family

ID=34951939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815224T ATE397676T1 (de) 2004-11-03 2005-11-03 Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen

Country Status (8)

Country Link
US (1) US20090029932A1 (de)
EP (1) EP1807536B1 (de)
AT (1) ATE397676T1 (de)
CA (1) CA2586275A1 (de)
DE (1) DE602005007373D1 (de)
ES (1) ES2308575T3 (de)
FR (1) FR2877350B1 (de)
WO (1) WO2006048553A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290066B1 (de) 2004-05-28 2015-03-18 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
WO2008073922A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
ES2534303T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
JP5489459B2 (ja) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
US8481505B2 (en) * 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
EP1940456A4 (de) * 2005-10-05 2009-10-21 Univ Ohio State Res Found Wwox-gen, vektoren damit und seine verwendung bei der krebsbehandlung
AU2007205257B2 (en) 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
EP2471956A1 (de) 2006-01-05 2012-07-04 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von festen Krebsen
EP1978986B1 (de) 2006-01-05 2013-08-07 The Ohio State University Research Foundation Mikro-rna-basierte verfahren zur diagnose und prognose von lungenkrebs
JP5523825B2 (ja) 2006-03-20 2014-06-18 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト巨核球形成間のマイクロｒｎａフィンガープリント
ES2447850T3 (es) 2006-07-13 2014-03-13 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el pronóstico y tratamiento de enfermedades relacionadas con el colon
EP2145001A2 (de) * 2006-09-19 2010-01-20 Asuragen, Inc. Von mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulierte gene und stoffwechselwege als ziele für einen therapeutischen eingriff
JP5426383B2 (ja) 2006-09-19 2014-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 慢性リンパ球性白血病におけるｍｉＲ−２９およびｍｉＲ−１８１によって制御されるＴＣＬ１発現
AU2007299804A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
EP2087135B8 (de) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Mikro-rna-expressionssignatur zur vorhersage des überlebens und von metastasen bei hepatozellulärem karzinom
US20090092974A1 (en) * 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2109687B1 (de) 2007-01-31 2014-06-04 The Ohio State University Research Foundation Micro-rna-basierte verfahren zur behandlung von akuter myeloischer leukämie (aml)
EP2481806B1 (de) * 2007-04-30 2016-11-09 The Ohio State University Research Foundation Verfahren zur Prognosis von Bauchspeicheldrüsenkrebs
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090227533A1 (en) * 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
CA2690144A1 (en) 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
JP2010535473A (ja) 2007-08-03 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン ｎｃＲＮＡをコードする超保存領域
JP5770472B2 (ja) 2007-08-22 2015-08-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ヒト急性白血病におけるｅｐｈａ７及びｅｒｋリン酸化の調節解除を誘発するための方法及び組成物
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20100285471A1 (en) * 2007-10-11 2010-11-11 The Ohio State University Research Foundation Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
BRPI0818901A2 (pt) 2007-11-09 2015-05-12 Univ Texas Micro-rnas da família mir-15 modulam sobrevivência de cardiomiócitos e reparo cardíaco
AU2008329755A1 (en) * 2007-11-30 2009-06-04 The Ohio State University Research Foundation MicroRNA expression profiling and targeting in peripheral blood in lung cancer
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2009091904A2 (en) * 2008-01-15 2009-07-23 The Johns Hopkins University Microrna based methods and compositions for the treatment of cancer
EP2260110B1 (de) * 2008-02-08 2014-11-12 Asuragen, INC. In lymphknoten von krebspatienten differentiell exprimierte mirnas
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
CA2717026A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
US20090258928A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
EP2285960B1 (de) 2008-05-08 2015-07-08 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-184modulation von neovaskularisation oder angiogenese
EP2307028B1 (de) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Verwendung der mir-26-familie als prädiktiver marker für hepatozelluläres karzinom und des ansprechens auf die therapie
WO2010017510A1 (en) * 2008-08-07 2010-02-11 University Of Southern California A system for synergistic expression of multiple small functional rna elements
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US8946187B2 (en) 2010-11-12 2015-02-03 The Ohio State University Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
CA2828772A1 (en) 2011-03-07 2012-09-13 The Ohio State University Mutator activity induced by microrna-155 (mir-155) links inflammation and cancer
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
EP2574357B1 (de) * 2011-09-28 2013-11-13 Q-Med AB Elektronischer Injektor
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
CN107217055B (zh) * 2017-06-26 2019-01-18 生工生物工程（上海）股份有限公司 一种癌症诊断芯片及其试剂盒
CN113528432B (zh) * 2021-07-19 2024-04-19 东北林业大学 一种利用miR-18抑制剂促牛成肌细胞分化的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038176A1 (fr) * 1995-06-01 1996-12-05 Kishimoto, Tadamitsu Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1)
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
EP2224003B1 (de) * 2001-09-28 2018-04-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MikroRNA-Moleküle
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2005047505A2 (en) * 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Methods and products for expression of micro rnas
EP1713938A2 (de) * 2004-02-09 2006-10-25 Thomas Jefferson University Diagnose und behandlung von krebserkrankungen mit oder nahe mit krebs in zusammenhang stehenden chromosomalen merkmalen lokalisierter microrna

Also Published As

Publication number Publication date
CA2586275A1 (fr) 2006-05-11
EP1807536A1 (de) 2007-07-18
ES2308575T3 (es) 2008-12-01
EP1807536B1 (de) 2008-06-04
FR2877350B1 (fr) 2010-08-27
DE602005007373D1 (de) 2008-07-17
FR2877350A1 (fr) 2006-05-05
US20090029932A1 (en) 2009-01-29
WO2006048553A1 (fr) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE397676T1 (de) Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen
DE60323340D1 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
DE602007013559D1 (de) Nanoteilchen zur abgabe von nukleinsäure
CY1114443T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
EP2057268A4 (de) Dna-impfstoff zur heilung von chronischer hepatitis b und verfahren zur herstellung davon
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
BR0315689A (pt) Alvo para terapia de dano cognitivo
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
DE602004029827D1 (de) Verfahren zur extraktion von fulvinsäuremolekülen
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
ATE452883T1 (de) KRISTALLINE FORM VON 1-CHLOR-4-(ß-D-GLUCOPYRANOS- 1-YL)-2-Ä4-((S)-TETRAHYDROFURAN-3-YLOXY)- BENZYLÜBENZOL, VERFAHREN ZU DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ZUR HERSTELLUNG VON MEDIKAMENTEN
EP2240131A4 (de) Vorrichtung, system und verfahren zur behandlung von adipositas
DE602005016292D1 (de) Verfahren zur herstellung von glatiramer
DE602008006410D1 (de) Verfahren zur behandlung von zellkulturmedien für die verwendung in einem bioreaktor
EP1902127A4 (de) Bioreaktorsystem und verfahren zur verbesserung der funktionalität von in vitro kultiviertem muskel
ATE477798T1 (de) Verwendung von agomelatin zur herstellung von medikamenten zur behandlung der generalisierten angststörung
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
ATE414277T1 (de) Verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen
DE602006009901D1 (de) Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin
DE112005001530T5 (de) Verfahren zur Spektralidentifikation von Mikroorganismen
EP2037736A4 (de) Verfahren zur behandlung von zystennierenerkrankungen
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
EP1789592A4 (de) Verfahren zur identifizierung und quantifizierung von kurzen oder kleinen rna-molekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties